Astria Therapeutics Inc ATXS
News
Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema
Astria Therapeutics to Present at Upcoming Global Angioedema Forum
Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference
Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
Astria Therapeutics Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema
Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)